FDA reviewers question efficacy of BioMarin's DMD therapy

In briefing documents released ahead of a Nov. 24 advisory committee meeting, FDA reviewers expressed doubts that Kyndrisa drisapersen from BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is effective to treat Duchenne muscular dystrophy (DMD). The reviewers intimated that the agency will use the meeting of the Peripheral and Central Nervous System Drugs Advisory Committee to

Read the full 539 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE